The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2023 | Challenges that have been faced with developing CAR-T products for CLL and future outlooks
Marco Ruella, MD, University of Pennsylvania, Philadelphia, PA, briefly discusses the challenges with developing efficacious CAR-T cell products for patients with chronic lymphocytic leukemia (CLL), and highlights the possibility of using combination approaches with Bruton’s tyrosine kinase (BTK) inhibitors as a therapeutic strategy in the future. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
